Clinical trials: Ankylosing Spondylitis
Ankylosing Spondylitis, Coxitis
Clinical and Radiological Manifestations of Coxitis in Patients With Ankylosing Spondylitis Treated With Golimumab
Rationale. Coxitis in AS is inflammation of hip(s) affecting significant number of patients. It is associated with worse function and more expressed axial disease requiring hip replacement at end-stage.
- Trial name
- GO-COX (NCT03557853)
- Testing
- Golimumab Injection
- Where
- 6 sites in Russia
- Volunteers
- 39 people
- Sponsor
- MSD Pharmaceuticals LLC
Spondylarthritis, Psoriatic Arthritis
A Study to Assess Retention Rate, Persistence and Adherence in Population of Spondylarthritis (Ankylosing Spondylitis and Psoriatic Arthritis) Patients Treated With Adalimumab in Routine Clinical Settings in Russian Federation
The objective of this study is to access retention rate, persistence and adherence in population of spondylarthritis (SpA) (ankylosing spondylitis (AS) and psoriatic arthritis (PsA)) participants treated with adalimumab in…
- Conditions
- Spondylarthritis, Psoriatic Arthritis, Ankylosing Spondylitis (AS)
- Trial name
- Adherence (NCT02988674)
- Where
- 14 sites in Russia
- Volunteers
- 139 people
- Sponsor
- AbbVie
Ankylosing Spondylitis (AS)
BI 655066 (Risankizumab) Proof of Concept Dose Finding Study in Ankylosing Spondylitis (AS)
The overall purpose of the trial is to assess the clinical efficacy of three different subcutaneous doses of BI 655066 (risankizumab) in adult patients with AS, in order to provide clinical proof of concept and to select dose (s)…
- Trial name
- NCT02047110
- Testing
- risankizumab
- Volunteers
- 159 people
- Sponsor
- AbbVie
Non-radiographic Spondyloarthritis
Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis
The purpose of this study was to demonstrate the clinical efficacy, safety and tolerability of secukinumab compared to placebo in patients with nr-axSpA at Week 16 as well as Week 52 and long term efficacy and safety up to Week…
- Trial name
- PREVENT (NCT02696031)
- Testing
- Secukinumab
- Where
- 139 sites in United States, Australia and 22 more
- Volunteers
- 555 people
- Sponsor
- Novartis Pharmaceuticals
Age-Related Macular Degeneration, Allergies
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and…
- Conditions
- Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease
- Trial name
- NCT05635266
- Testing
- Specimen sample
- Where
- United States
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Spondylitis, Ankylosing
A Study of the Efficacy and Tolerance of Remicade in the Treatment of Active Ankylosing Spondylitis (Study P04042)(COMPLETED)
The objective of this study is to prove reasonability of registration in Russian federation this new indication (ankylosing spondylitis [AS]) through evaluation of safety and efficacy rate of Remicade 5mg/kg, given as an…
- Trial name
- NCT00779012
- Testing
- Infliximab
- Volunteers
- 42 people
- Sponsor
- Merck Sharp & Dohme LLC
Ankylosing Spondylitis
Extension Study to Evaluate Safety and Efficacy of Jaktinib in Patients With Active Ankylosing Spondylitis(AS)
The purpose of this study is to determine if Jaktinib is safe and effective in participants with active ankylosing spondylitis.
- Trial name
- NCT05861128
- Testing
- Jaktinib
- Where
- China
- Volunteers
- 207 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Inflammatory Bowel Disease
Analysis of Birth Outcomes of Swedish, Danish and Finnish Women Exposed to Remicade With Inflammatory Bowel Disease, Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Psoriasis
The purpose of this study is collection and analysis of information pertaining to pregnancy outcomes in women exposed to infliximab during pregnancy, relative to the background risk in similar but non-biologic exposed patients…
- Trial name
- NCT00658827
- Testing
- No intervention
- Volunteers
- 370 people, healthy volunteers welcome
- Sponsor
- Janssen Biotech, Inc.
Ankylosing Spondylitis
Real-world Study on Secukinumab Effectiveness in Biologic-naïve Ankylosing Spondylitis (AS) Patients in Korea.
This is an observational study to evaluate the effectiveness and safety of secukinumab in participants with AS who have never used TNFi, JAKi, or IL-17i drugs before.
- Trial name
- ONSET (NCT06905288)
- Testing
- Secukinumab
- Where
- 3 sites in South Korea
- Volunteers
- 70 people
- Sponsor
- Novartis Pharmaceuticals
Ankylosing Spondylitis
Efficacy and Safety of Adalimumab in Adult Chinese Subjects With Active Ankylosing Spondylitis
Study of the efficacy and safety of adalimumab compared with placebo in adult Chinese participants with ankylosing spondylitis (AS) who have had an inadequate response to or who are intolerant to one or more nonsteroidal…
- Trial name
- NCT01114880
- Testing
- adalimumab
- Where
- 9 sites in China
- Volunteers
- 344 people
- Sponsor
- Abbott
Ankylosing Spondylitis
Evaluate the Efficacy, Safety, and Pharmacokinetic Profile and Immunogenicity of Subcutaneous Netakimab in Chinese Adult Patients With Active Ankylosing Spondylitis
The goal of this clinical trial is to To evaluate the efficacy of subcutaneous (SC) Netakimab in adult Chinese patients with Active Ankylosing Spondylitis.
- Trial name
- NCT07277179
- Testing
- Netakimab
- Where
- China
- Volunteers
- 113 people
- Sponsor
- SPH-BIOCAD (HK) Limited
Active Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis
Efficacy and Safety Study of SUNPG1622
This is a randomized, double-Blind, placebo-controlled Phase 2a study to evaluate the efficacy and safety of SUNPG1622.
- Trial name
- NCT02980705
- Testing
- SUNPG1622 I dose
- Where
- 4 sites in United States, Hungary and 2 more
- Volunteers
- 180 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Rheumatoid Arthritis, Arthritis, Psoriatic
Golimumab Safety and Surveillance Program Using the Ingenix NHI Database
The participants included in this observational study will be drawn from a research database containing claims and enrollment data for members of a large, geographically diverse US health plan.The objective of this study is to…
- Conditions
- Rheumatoid Arthritis, Arthritis, Psoriatic, Ankylosing Spondylitis
- Trial name
- NCT01081717
- Testing
- systemic non-biological treatments, anti-TNF biologics, golimumab
- Volunteers
- 1,064 people
- Sponsor
- Janssen Biotech, Inc.
Rheumatoid Arthritis, Ankylosing Spondylitis
An Observational, Prospective Study to Assess the Efficacy and Safety of Adalloce in Patients With RA and AS
This Study is to Assess the Efficacy and Safety of Adalloce in Patients With Rheumatoid Arthritis and Ankylosing Spondylitis, An Observational, Prospective Study
- Trial name
- NCT05835518
- Where
- South Korea
- Volunteers
- 1,000 people
- Sponsor
- Yuhan Corporation
Spondylitis, Ankylosing
Study Comparing Etanercept (ETN) Against a Placebo for Etanercept on a Background Nonsteroidal Anti Inflammatory Drug (NSAIDs) in the Treatment of Early Spondyloarthritis (SpA) Patients Who do Not Have X-ray Structural Changes
This is a two part study. During period one there will be a comparison of Etanercept (ETN) against a placebo with both arms maintaining the background anti inflammatory drug prescribed by their Physician.
- Trial name
- EMBARK (NCT01258738)
- Testing
- etanercept, Background NSAID
- Where
- 50 sites in Argentina, Belgium and 12 more
- Volunteers
- 225 people
- Sponsor
- Pfizer
Spondylitis, Ankylosing
Etanercept Withdrawal And Retreament Study In Subjects With Nr-ax SpA
The purpose of this study is to study the benefits and risks of etanercept withdrawal in patients who have achieved a significant clinical response.
- Trial name
- RE-EMBARK (NCT02509026)
- Testing
- Etanercept
- Where
- 82 sites in United States, Australia and 12 more
- Volunteers
- 210 people
- Sponsor
- Pfizer
Ankylosing Spondylitis
Study of Efficacy and Safety of Secukinumab in Japanese Patients With Active Ankylosing Spondylitis
The purpose of this study was to assess the clinical efficacy, safety and tolerability of secukinumab subcutaneous injections up to 52 weeks in Japanese patients with active AS despite current or previous non-steroidal…
- Trial name
- NCT02750592
- Testing
- Secukinumab 150 mg provided in 1.0 mL pre-filled syringes (PFSs) for sc injection.
- Where
- 10 sites in Japan
- Volunteers
- 30 people
- Sponsor
- Novartis Pharmaceuticals
Ankylosing Spondylitis, Arthritis, Psoriatic
Study Evaluating the Safety of Etanercept in Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis
This is a Phase 4 open label, non-interventional, multi-center study to evaluate the safety of Enbrel (etanercept) treatment in patients receiving etanercept 25mg sc twice weekly or 50mg of etanercept once weekly.
- Conditions
- Ankylosing Spondylitis, Arthritis, Psoriatic, Arthritis, Rheumatoid, Spondylitis, Ankylosing
- Trial name
- NCT00273858
- Testing
- There is no Intervention. The study is observational.
- Where
- 9 sites in Greece
- Volunteers
- 880 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Axial Spondyloarthritis
Study of Efficacy and Safety of Brodalumab Compared With Placebo in Subjects With Axial Spondyloarthritis
The purpose of this study is to assess the safety and efficacy of brodalumab compared with placebo in participants with axial spondyloarthritis.
- Trial name
- NCT02429882
- Testing
- Brodalumab 210 mg
- Where
- 5 sites in United States, Canada
- Sponsor
- Amgen
Rheumatoid Arthritis, Spondyloarthropathies
Benepali® PEN Patient Satisfaction Survey
The main aim of this study is to ascertain general satisfaction among participants with rheumatic diseases with day-to-day use of the Benepali® prefilled pen by means of a standardised participant questionnaire.
- Trial name
- NCT03327454
- Testing
- Benepali
- Where
- 38 sites in Germany
- Volunteers
- 500 people
- Sponsor
- Biogen